Jb Chemicals & Pharmaceuticals Ltd. · NSE:JBCHEPHARM
Jb Chemicals & Pharmaceuticals — Q2 FY23 Earnings Presentation
24 slides from Jb Chemicals & Pharmaceuticals's earnings presentation, Nov 11, 2022
Slide 1: Cover letter to National Stock Exchange
November 11, 2022 National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G-Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400051. Stock Symbol: JBCHEPHARM Dear Sir, Subject: Investor Presentation Enclosed please find the presentation the Company proposes to make to inve
Slide 2: JB Pharma – Q2 and H1 FY23 Financial Results
JB Pharma – Q2 and H1 FY23 Financial Results November 11, 2022 www.jbpharma.com jbpharma/ 1
Slide 3: Disclaimer
Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the d
Slide 4: Corporate Overview
Corporate Overview 3
Slide 5: Corporate Snapshot
Corporate Snapshot Years of operations with Brands among top 300 brands, 46 consistent track record across multiple businesses 5 contributing over 60% of domestic formulations revenues Regulated/semi-regulated Global manufacturer of 40+ markets of presence through direct operations and Top 5 medicat
Slide 6: Corporate Snapshot – Financial Overview
Corporate Snapshot – Financial Overview Revenue (INR cr) PAT (INR cr) *Op EBITDA Margin (%) 42% 27.4% 25.0% 29% 21.3% 24% 22% 18.6% 15.4% 15% 25% 2,424 2,043 19% 18% 1,643 1,775 1,413 13% 10% 272 449 386 139 194 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 ROE (%) ROCE (%) Increasing Share of t
Slide 7: World Class Manufacturing Facilities
World Class Manufacturing Facilities Seven state-of-the-art manufacturing facilities in Western India Over 40 global regulatory accreditations US FDA EU – GMP HEALTH – Canada SAHPRA – South Africa MHRA – UK TGA – Australia MOH – Russia Producing a wide array of dosage forms 6
Slide 8: Q2 and H1 FY23 Business Performance
Q2 and H1 FY23 Business Performance 7
Slide 9: CEO’s Message
CEO’s Message “We continue to build further on our strong operating performance across business segments in FY 23. Our market-beating performance in domestic business was sustained through growth in our organic portfolio, with big brands getting bigger; and significant demand acceleration in acquire
Slide 10: Financial Overview: Q2 and H1 FY23
Financial Overview: Q2 and H1 FY23 Revenues (INR cr) o JB continued its strong growth momentum, registering YoY growth 33% of 36% in Q2 FY23 and 33% in H1 FY23 1,594 36% 1,199 809 o Domestic Formulations business maintained its market beating 593 performance growing at 45% in Q2 FY23 and 38% in H1 F
Slide 11: EBITDA Analysis
EBITDA Analysis INR crore Q2 FY23 Q2 FY22 H1 FY23 H1 FY22 Revenue 809 593 1594 1199 Reported EBITDA 185 127 358 290 Non Cash ESOPs 17 13 34 13 Included in Employee Benefits expense Operating EBITDA (excluding ESOP costs) 202 140 392 303 Operating EBITDA margins 25.0% 23.6% 24.6% 25.3% One time consu
Slide 12: Financial Overview Q2 and H1 FY23
Financial Overview Q2 and H1 FY23 Op. EBITDA* (INR cr) Op. EBITDA Margin (%) o Operating EBIDTA* improved by 44% in Q2 FY23 and 29% in H1 FY23 25.3% • Operating EBITDA* margin was at 25% in Q2 FY23 vs 23.6% in Q2 25.0% FY22 24.6% • Strong operating leverage 29% 392 23.6% o Gross margins was 62.7% in
Slide 13: Domestic Business Q2 and H1 FY23
Domestic Business Q2 and H1 FY23 o Domestic business continued to register INR 400+ crores revenue for the Domestic Formulations (INR cr) second consecutive quarter o Domestic business, excluding sales from acquired brands, grew at mid- teens, out-pacing industry growth 38% 853 o New Product contrib
Slide 14: JB continues to be one of the fastest growing companies in its CVM
JB continues to be one of the fastest growing companies in its CVM, maintaining a market beating performance Among top 25, JB is the fastest Leadership position Fastest growing growing pharma company in the IPM in the covered markets company among the Top 25 in the IPM 19% Vs IPM growth of 7% 35% +
Slide 15: Prescription wise JB on 15th rank in IPM
Prescription wise JB on 15th rank in IPM 450.0 400.0 56% #15 Prescription Ranking 412.2 350.0 300.0 • JB’s prescriptions increased to 4.12 crores in Q2 250.0 265.1 FY23 as compared to 2.65 crores in Q2 FY22 200.0 recording growth of 55% 150.0 13% 100.0 • Prescribers(Rxbers) increased by 13% to 50.0
Slide 16: Revenue Analysis: International Business Q2 and H1 FY23
Revenue Analysis: International Business Q2 and H1 FY23 28% 375 17% 294 242 206 64% 110 10% 67 21 23 o The International business continues its strong performance with revenue growing at 28% in Q2 FY23 as well as H1 FY23 Total International CMO API International Formulations • International business
Slide 17: Q2 and H1 FY23 Financial Performance (Consolidated)
Q2 and H1 FY23 Financial Performance (Consolidated) Particulars Q2 FY23 Q2 FY22 YoY Growth H1 FY23 H1 FY22 YoY Growth Revenue from Operations 809 593 36% 1594 1199 33% Cost of Goods Sold 302 208 45% 594 424 40% Gross Profit 508 385 32% 1000 775 29% Gross Profit Margins 62.7% 65.0% 62.7% 64.6% Employ
Slide 18: Abridged Balance Sheet as on Sept 30, 2022
Abridged Balance Sheet as on Sept 30, 2022 Balance Sheet (INR cr) as on 30 Sept'22 31 Mar'22 o Free cash flow continues to be strong for the company Net Worth 2,315 2,134 o Improvement seen in net working capital viz. Borrowings 350 26 Inventory and receivables days have improved Other Liabilities 2
Slide 19: Consistent and high cash flow generation
JB Pharma - Consistent and high cash flow generation Particulars (INR cr) H1 FY 23 Profit before tax 292 Net cash flows generated from operating activities A 279 Net Cash (used in) Investing activities# B (377) Net cash flow generated/(used in) financing activities C 244 Net increase in cash and cas
Slide 20: JB Pharma – Looking ahead – FY 2023
JB Pharma – Looking ahead –FY 2023 Domestic business should consistently outperform market growth Acquired Brands will continue to gain traction in this financial year International business should continue to deliver good sales growth Demand from Export formulations esp. the ROW business re
Slide 21: JB Pharma Releases its Maiden Sustainability Report
JB Pharma Releases its Maiden Sustainability Report 20
Slide 22: Sustainability Report – FY 2021-22
Sustainability Report – FY 2021-22 Reporting Framework: Report prepared in accordance with the GRI Standards: Core Option, and United Nations Sustainable Development Goals (UN SDGs) Reporting Period: This report covers the sustainability performance of the Company for the period 1st April 2021 till
Slide 23: About JB Pharma
About JB Pharma J.B. Pharma (BSE: 506943 | NSE: JBCHEPHARM | For further information, please ISIN: INE572A01028), established in 1976, is one contact: of the fastest growing pharmaceutical companies in India and a leading player in the hypertension Lakshay Kataria, Chief Financial Officer segment. B
Slide 24: Thank you
Thank you www.jbpharma.com 23
J.B. Chemicals & Pharmaceuticals — Q2 FY23 Earnings Presentation on 6ix